The Medicare GLP-1 Bridge

A Medicare pathway offering a fixed monthly cost for a covered GLP-1 has been widely reported, with clinical eligibility criteria and several exclusions. This page sets out what is reported, and is explicit about what we have been unable to confirm.

Pricing data as of 2026-07-30.

What is reported

The program is reported to provide a fixed low monthly cost to eligible Medicare beneficiaries, subject to a BMI threshold, with a further route in at a lower BMI where a weight-related comorbid condition is present. It is reported to cover a multi-dose pen rather than single-dose vials, and to exclude beneficiaries whose therapy is already covered under the obstructive sleep apnea indication.

What we could not confirm, and what we did about it

We could not reach CMS to confirm any of it: whether the program launched on its reported date, its actual eligibility criteria, or its actual beneficiary cost. The refusals we hit on 2026-07-30 came from our own network rather than from CMS, but the effect is the same: we have not read those pages.

So the cost renders as unverified rather than as a number. The exclusions, however, we apply anyway, because applying them is the cautious direction. If we are wrong about the sleep apnea exclusion, we have told an eligible beneficiary to check with Medicare. If we omitted it and it is real, we would have quoted a price to someone who cannot get it. Between those two errors there is no contest.

Confirm your own eligibility with Medicare directly before relying on anything here.

If you are on Medicare, the savings card is not an option

Manufacturer copay and savings cards exclude anyone enrolled in a federal healthcare program. Our tool removes that pathway entirely for Medicare and Medicaid beneficiaries rather than showing a low copay you cannot claim. What remains available is this program, standard Part D coverage where your plan covers the indication, and cash-pay direct programs.

Every figure we hold for this pathway

Compare it against everything else

A single pathway in isolation cannot tell you whether it is your cheapest option. Use the tool to rank this pathway against every other one for your medication, your insurance situation and your dose.